|
|
Article: Evotec Initiates its First Phase I Clinical Study With EVT 302.
- Article from:
- PR Newswire
- Article date:
- March 22, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HAMBURG, Germany and OXFORD, England, March 22 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) announced today the initiation of its first Phase I study with EVT 302. This open-label study is designed to access the occupancy of the monoamine oxidase B enzyme (MAO-B) in brain after administration of single oral doses of EVT 302 by the use of dynamic positron emission tomography (PET). This technique helps to determine the therapeutic dose range of EVT 302 for the upcoming safety and efficacy studies.
EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B in development for smoking cessation. Its preclinical ...